Coeliac plexus block for upper abdominal cancer pain

Chambers, Pauline C.
July 2003
British Journal of Nursing;7/24/2003, Vol. 12 Issue 14, p838
Academic Journal
Examines the use of celiac plexus block to relieve intractable pain due to upper abdominal cancer. Percentage of patients reporting significant relief, allowing a reduction in opioid use and the occurrence of opioid-related side effects; Variations in the duration of relief.


Related Articles

  • Management of Pain in Patients with Cancer. Miller, Karl E. // American Family Physician;2/1/2000, Vol. 61 Issue 3, p835 

    Discusses research on management of pain in cancer patients. Reference to a study by J. L. Abrahm, from the July 6, 1999 issue of the `Annals of Internal Medicine'; Problems of pain and spinal cord compression experienced by cancer patients; Assessment of pain intensity; Prescription of opioids...

  • Treating neuropathic pain in cancer. Harman, Stephanie // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p34 

    The article presents information on the treatment of neuropathic pain in patients diagnosed with cancer.

  • Antinociceptive Effect of Intrathecal Microencapsulated Human Pheochromocytoma Cell in a Rat Model of Bone Cancer Pain. Xiao Li; Guoqi Li; Shaoling Wu; Baiyu Zhang; Qing Wan; Ding Yu; Ruijun Zhou; Chao Ma // International Journal of Molecular Sciences;Jul2014, Vol. 15 Issue 7, p12135 

    Human pheochromocytoma cells, which are demonstrated to contain and release met-enkephalin and norepinephrine, may be a promising resource for cell therapy in cancer-induced intractable pain. Intrathecal injection of alginate-poly (L) lysine-alginate (APA) microencapsulated human...

  • Management of cancer pain: ESMO Clinical Practice Guidelines. Jost, L.; Roila, F. // Annals of Oncology;May2010, Vol. 21 Issue suppl_5, pv257 

    The article focuses on the guidelines of the European Society for Medical Oncology (ESMO) for managing cancer pain. It says that analgesic therapy for cancer pain must follow the World Health Organization's (WHO) pain ladder including non-opioid analgesics or non-steroidal inflammatory drugs...

  • Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion. Sutton, S. W.; Yancey, L. W.; Chase, V. A.; Hunley, E. K.; McCarty, T. M.; Kuhn, J. A.; Loggie, B. W. // Perfusion;Nov2002, Vol. 17 Issue 6, p441 

    The use of hyperthermia as an adjunct to chemotherapy in the treatment of peritoneal carcinomatosis is a promising technique for patients who otherwise have a poor prognosis for survival. We, herein, report an overview and description of our technique for the safe conduct of this treatment....

  • Scrambler Therapy for Patients with Cancer Pain. Hong Sik Park; Woo Kyung Sin; Hye Young Kim; Jee Youn Moon; Soo Young Park; Yong Chul Kim; Sang Chul Lee // Korean Journal of Pain;Jan2013, Vol. 26 Issue 1, p65 

    More than 80% of cancer patients experience cancer pain. Among them, more than 50% experience moderate to severe pain. To control cancer pain, a variety of methods have been used, including medications and nerve blocks. In some patients, however, it is impossible to perform nerve blocks due to...

  • The challenges of cancer pain assessment and management. Campbell, Victoria // Ulster Medical Journal;May2011, Vol. 80 Issue 2, p104 

    The article focuses on the challenges in assessing and managing cancer pain which is present in 36 to 61 percent of patients. Assessment is the first step to pain management which involves detailed history and physical examination, psychosocial assessment and a diagnostic work-up. Cancer pain...

  • Management of cancer pain: ESMO Clinical Recommendations. Jost, L.; Roila, F. // Annals of Oncology;May2009 Supplement 4, Vol. 20, piv170 

    The article presents clinical recommendations for the management of cancer pain from the European Society for Medical Oncology (ESMO). The incidence of pain is based on the fact that over 80 percent of cancer patients with advanced metastatic disease suffer pain due to direct tumor infiltration....

  • OROS Hydromorphone Prolonged Release. Carter, Natalie I.; Keating, Gillian M. // CNS Drugs;2010, Vol. 24 Issue 4, p337 

    OROS® hydromorphone prolonged release (OROS® hydromorphone) [Jurnista™] is a once-daily formulation of the opioid agonist hydromorphone that utilizes OROS® (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate, thereby providing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics